<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903537</url>
  </required_header>
  <id_info>
    <org_study_id>TOLERVIT-MS</org_study_id>
    <secondary_id>2015-003541-26</secondary_id>
    <nct_id>NCT02903537</nct_id>
  </id_info>
  <brief_title>Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)</brief_title>
  <acronym>TOLERVIT-MS</acronym>
  <official_title>Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut Germans Trias i Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut Germans Trias i Pujol</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of the intranodal
      administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and
      pulsed with myelin peptides (tolDC-VitD3) in multiple sclerosis patients . To select the most
      appropriate regime for the development of future therapeutic trials.

      To evaluate the preliminary proof of concept by clinical and/or radiological activity and
      immunological markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I dose ascending (&quot;best of five&quot;) clinical trial.

      First group will start by intranodal injection in cervical lymph nodes of 5*10^6 tolDC-VitD3.

      Up titration depending on security outcomes to 10*10^6 tolDC-VitD3, same route in second
      cohort dose and next uptitration to 15*10^6 tolDC-VitD3.

      Six cycles per patient with the following schema: for the first four cycles the
      administration will be each 2 weeks, for the remaining 2 cycles administration each 4 weeks.

      A last cohort with the dose identified in the previous groups, administered in patients
      treated with beta interferon, same route, same dose schema.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by the occurrence and severity of adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Occurence and severity of adverse events will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurologic changes</measure>
    <time_frame>24 months</time_frame>
    <description>New relapse. Disability progression on Expanded Disability Status Scale (EDSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic changes</measure>
    <time_frame>24 months</time_frame>
    <description>Number of new or enlarging T2 lesions on brain MRI. Number of Gadolinium (Gd)-enhancing T1 lesions on brain MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual relapse rate (ARR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Test (9HPT)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-Foot Walking Test (T25FW)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic preliminary efficacy</measure>
    <time_frame>24 months</time_frame>
    <description>Number of new or enlarging T2 lesions on brain MRI. Number of Gadolinium (Gd)-enhancing T1 lesions on brain MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte proliferation to myelin peptides</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Immunomonitoring studies</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>6 months</time_frame>
    <description>Generation of Good Manufacturing Practices (GMP)-grade cell product released according to Quality Control. Feasibility of cellular product injection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Multiple Sclerosis, Chronic Progressive</condition>
  <arm_group>
    <arm_group_label>5 * 10 ^6 tolDC-VitD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 * 10 ^6 tolDC-VitD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 * 10 ^6 tolDC-VitD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon-beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)</intervention_name>
    <description>Intranodal administration</description>
    <arm_group_label>5 * 10 ^6 tolDC-VitD3</arm_group_label>
    <arm_group_label>10 * 10 ^6 tolDC-VitD3</arm_group_label>
    <arm_group_label>15 * 10 ^6 tolDC-VitD3</arm_group_label>
    <arm_group_label>Interferon-beta</arm_group_label>
    <other_name>tolDC-VitD3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-beta</intervention_name>
    <description>Subcutaneous administration interferon-beta</description>
    <arm_group_label>Interferon-beta</arm_group_label>
    <other_name>beta-interferon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. EDSS of 0.0 - 6.5.

          2. Multiple Sclerosis according to 2010 revised Mc Donald criteria, and less than 15
             years of evolution of disease.

          3. Patients with:

               -  Active relapsing remitting multiple sclerosis (RRMS) (more than 1 relapse in last
                  year and/or occurrence of ≥3 new T2 lesions or Gd positive) who not wish to be
                  treated with current therapies.

               -  Low activity RRMS (1 relapse in last year or occurrence of 1 or 2 T2 lesions or
                  Gd positive) without treatment.

               -  Progressive forms of MS with activity (at least 1 relapse in last year or
                  occurrence 1 or 2 T2 lesions or Gd positive).

               -  RRMS treated with interferon beta (Additional group)

          4. T cell proliferation to the pool of myelin peptides against which is to induce immune
             tolerance: Myelin basic protein (MBP)13-32, MBP83-99, MBP111-129, MBP146-170,
             proteolipid protein (PLP) 139-154, Myelin oligodendrocyte glycoprotein (MOG)1-20,
             MOG35 -55).

          5. Adequate peripheral venous access.

          6. Signed informed consent.

        Exclusion Criteria:

          1. Use of corticosteroids during the prior 4 weeks.

          2. Use of interferon beta -in patients who is retired by inefficiency or other causes-
             and glatiramer acetate in the 4 weeks prior.

          3. Use of fingolimod, dimethylfumarate, natalizumab, immunoglobulins or plasmapheresis at
             12 weeks; and teriflunomide in the 15 weeks prior.

          4. Use of azathioprine, mitoxantrone, rituximab, methotrexate, cyclophosphamide,
             cyclosporine, alemtuzumab or other immunosuppressive drug, except corticosteroids, at
             any time.

          5. Bone marrow or stem cell transplant at any time.

          6. Relapse during the month prior of starting treatment. If it appears and the patient
             meets the eligibility criteria, must wait long enough until the end of the 30 days
             free of relapse. If corticosteroids are administered, the MRI performed during this
             period should not be considered, and a new MRI will be performed at 4 weeks after
             administration of corticosteroids.

          7. Pregnancy or planning pregnancy within the next 12 months and breastfeeding.

          8. Fertile patients who are not using an appropriate method of contraception. If the
             patient is menopausal or sterile it must be documented in the medical record.

          9. Abusing drugs or alcohol.

         10. Inability to undergo MRI evaluations.

         11. Seropositivity for HIV, hepatitis B or C and/or syphilis.

         12. History of oncological disease.

         13. Clinically relevant concomitant disease: cardiac, pulmonary, neurological, renal or
             other major illness.

         14. Splenectomy.

         15. Dementia, psychiatric problems or other comorbidities that might interfere protocol
             compliance.

         16. To be participating in another clinical study or to have participated in one in the
             last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Ramo, MD.PhD.Neurologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Badalona Hospital Germans Trias i Pujol. Neurology service. Multiple Sclerosis department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Martínez-Cáceres, MD.PhD.Immunology</last_name>
    <role>Study Director</role>
    <affiliation>Badalona Hospital Germans Trias i Pujol. Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Ramo, MD.PhD. Neurologist</last_name>
    <phone>+34934978433</phone>
    <email>cramot.germanstrias@gencat.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana M Barriocanal, MD.PhD.Clinical Pharmacologist</last_name>
    <phone>+34934978488</phone>
    <email>ambarrioocanal@igtp.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Ramo, MD.PhD</last_name>
      <phone>+34934978433</phone>
      <email>cramot.germanstrias@gencat.cat</email>
    </contact>
    <contact_backup>
      <last_name>Ana M Barriocanal, MD.PhD</last_name>
      <phone>+34934978488</phone>
      <email>ambarriocanal@igtp.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Eva Martínez-Cáceres, MD.PhD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Presas, MD.Neurology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magí Farré, MD.PhD.Clinical Pharmacology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M Barriocanal, MD.PhD.Clinical Pharmacology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María J Mansilla, MD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bibiana Quirant, MD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aina Teniente, MD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Navarro, MD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Munuera, MD.Radiology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Massuet, MD.Radiology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Reverter, MD.Endocrine Intervention</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Suñol, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Gállego, MD.PhD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>3594</phone_ext>
      <email>jgallego@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Amaya Izal</last_name>
      <phone>+34948255400</phone>
      <phone_ext>2724</phone_ext>
      <email>aizal@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Jaime Gallego, MD.PhD. Neurology</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Purificación De Castro, MD.Neurology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Prosper, MD.Haematology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susana Inogés, MD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ascensión López, MD.Immunology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Andreu, MD.Cell therapy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Larrache, MD.Radiology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Azcona, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.afactt.eu</url>
    <description>European Cooperation in Science and Technology (COST), Action BM1305 &quot;Action to focus and accelerate cell-based tolerogenic therapies&quot;</description>
  </link>
  <reference>
    <citation>Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann JP, Breiden P, Reinhardt S, Schulze C, Bester M, Heesen C, Schippling S, Miller SD, Sospedra M, Martin R. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013 Jun 5;5(188):188ra75. doi: 10.1126/scitranslmed.3006168.</citation>
    <PMID>23740901</PMID>
  </reference>
  <reference>
    <citation>Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011 Sep;34(9):2026-32. doi: 10.2337/dc11-0472. Epub 2011 Jun 16.</citation>
    <PMID>21680720</PMID>
  </reference>
  <reference>
    <citation>Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, Pahau H, Lee BT, Ng J, Brunck ME, Hyde C, Trouw LA, Dudek NL, Purcell AW, O'Sullivan BJ, Connolly JE, Paul SK, Lê Cao KA, Thomas R. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. 2015 Jun 3;7(290):290ra87. doi: 10.1126/scitranslmed.aaa9301.</citation>
    <PMID>26041704</PMID>
  </reference>
  <reference>
    <citation>Naranjo-Gómez M, Raïch-Regué D, Oñate C, Grau-López L, Ramo-Tello C, Pujol-Borrell R, Martínez-Cáceres E, Borràs FE. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med. 2011 Jun 9;9:89. doi: 10.1186/1479-5876-9-89.</citation>
    <PMID>21658226</PMID>
  </reference>
  <reference>
    <citation>Raϊch-Regué D, Grau-López L, Naranjo-Gómez M, Ramo-Tello C, Pujol-Borrell R, Martínez-Cáceres E, Borràs FE. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol. 2012 Mar;42(3):771-82. doi: 10.1002/eji.201141835.</citation>
    <PMID>22488365</PMID>
  </reference>
  <reference>
    <citation>Mansilla MJ, Sellès-Moreno C, Fàbregas-Puig S, Amoedo J, Navarro-Barriuso J, Teniente-Serra A, Grau-López L, Ramo-Tello C, Martínez-Cáceres EM. Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis. CNS Neurosci Ther. 2015 Mar;21(3):222-30. doi: 10.1111/cns.12342. Epub 2014 Nov 18.</citation>
    <PMID>25403984</PMID>
  </reference>
  <reference>
    <citation>Raïch-Regué D, Naranjo-Gómez M, Grau-López L, Ramo C, Pujol-Borrell R, Martínez-Cáceres E, Borràs FE. Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy. Vaccine. 2012 Jan 5;30(2):378-87. doi: 10.1016/j.vaccine.2011.10.081. Epub 2011 Nov 12.</citation>
    <PMID>22085546</PMID>
  </reference>
  <reference>
    <citation>Ten Brinke A, Hilkens CM, Cools N, Geissler EK, Hutchinson JA, Lombardi G, Lord P, Sawitzki B, Trzonkowski P, Van Ham SM, Martinez-Caceres EM. Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort. Mediators Inflamm. 2015;2015:471719. doi: 10.1155/2015/471719. Epub 2015 Dec 24. Review.</citation>
    <PMID>26819498</PMID>
  </reference>
  <reference>
    <citation>Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl E, Dunn J, Dickinson AM, Hilkens CM, Isaacs JD. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017 Jan;76(1):227-234. doi: 10.1136/annrheumdis-2015-208456. Epub 2016 Apr 26.</citation>
    <PMID>27117700</PMID>
  </reference>
  <reference>
    <citation>Mansilla MJ, Contreras-Cardone R, Navarro-Barriuso J, Cools N, Berneman Z, Ramo-Tello C, Martínez-Cáceres EM. Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. J Neuroinflammation. 2016 May 20;13(1):113. doi: 10.1186/s12974-016-0584-9.</citation>
    <PMID>27207486</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Dendritic Cells</keyword>
  <keyword>Immune Tolerance</keyword>
  <keyword>Myelin Proteins</keyword>
  <keyword>Tolerogenic dendritic cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

